Theriva Biologics Files 8-K on Financials

TL;DR

Theriva Biologics filed an 8-K on Nov 12, 2024, reporting on financial condition and operations.

AI Summary

On November 12, 2024, Theriva Biologics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.

Why It Matters

This filing indicates Theriva Biologics is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor the company's health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting financial condition and operations, without immediate news of significant positive or negative events.

Key Players & Entities

• Theriva Biologics, Inc. (company) — Registrant
• November 12, 2024 (date) — Date of earliest event reported
• Synthetic Biologics, Inc. (company) — Former company name
• ADEONA PHARMACEUTICALS, INC. (company) — Former company name
• PIPEX PHARMACEUTICALS, INC. (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share TOVX NYSE American Indica

Filing Documents

• tm2426982d2_8k.htm (8-K) — 26KB
• tm2426982d2_ex99-1.htm (EX-99.1) — 110KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.jpg (GRAPHIC) — 4KB
• image_002.gif (GRAPHIC) — 3KB
• image_003.jpg (GRAPHIC) — 4KB
• image_004.jpg (GRAPHIC) — 4KB
• image_005.jpg (GRAPHIC) — 4KB
• image_006.jpg (GRAPHIC) — 4KB
• 0001104659-24-116420.txt ( ) — 356KB
• syn-20241112.xsd (EX-101.SCH) — 3KB
• syn-20241112_lab.xml (EX-101.LAB) — 33KB
• syn-20241112_pre.xml (EX-101.PRE) — 22KB
• tm2426982d2_8k_htm.xml (XML) — 4KB

02

Item 2.02. Results of Operations and Financial Condition. On November 12, 2024, Theriva Biologics, Inc., a Nevada corporation (the "Registrant") issued a press release that included financial information for its quarter ended September 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated November 12, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 12, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR